



Diagnosis and Management of HIV-2 in Adults

June 2023

Table 1: Preferred ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2 [a]

(listed alphabetically; for specific details, see drug package inserts; for full recommendations on initiating ART in patients with HIV-1, see the NYSDOH AI guideline [Selecting an Initial ART Regimen](#))

Regimen	Comments	Rating
<i>Available as a Single-Tablet Formulation</i>		
Abacavir/lamivudine/dolutegravir [b,c] (ABC/3TC/DTG; Triumeq)	<ul style="list-style-type: none"> Initiate only in patients confirmed to be negative for HLA-B*5701, including when a “rapid-start” or “test-and-treat” initiation of ART occurs before baseline laboratory test results are available. Initiate only in patients with CrCl ≥30 mL/min [d]. Consider underlying risk of coronary heart disease. Documented DTG resistance after initiation in treatment-naive patients is rare. Mg- or Al-containing antacids may be taken 2 hours before or 6 hours after DTG; Ca-containing antacids or iron supplements may be taken simultaneously if taken with food. 	A1
Tenofovir alafenamide/emtricitabine/bictegravir [c] (TAF 25 mg/FTC/BIC; Biktarvy)	<ul style="list-style-type: none"> Initiate only in patients with CrCl ≥30 mL/min [d]. Contains 25 mg of TAF, unboosted [c]. Mg- or Al-containing antacids may be taken 2 hours before or 6 hours after BIC; Ca-containing antacids or iron supplements may be taken simultaneously if taken with food. 	A1
<i>Available as a Multi-Tablet Regimen With Once-Daily Dosing</i>		
Tenofovir alafenamide/emtricitabine or tenofovir disoproxil fumarate/emtricitabine and dolutegravir [b,c] (TAF 25 mg/FTC or TDF 300 mg/FTC and DTG; Descovy or Truvada and Tivicay)	<ul style="list-style-type: none"> For TAF/FTC, initiate only in patients with CrCl ≥30 mL/min [d]. Contains 25 mg of TAF, unboosted [c]. For TDF/FTC, initiate only in patients with CrCl ≥50 mL/min [d]. For TDF/FTC, consider bone mineral density. Documented DTG resistance after initiation in treatment-naive patients is rare. Mg- or Al-containing antacids may be taken 2 hours before or 6 hours after DTG; Ca-containing antacids or iron supplements may be taken simultaneously if taken with food. 	A1
Tenofovir alafenamide/emtricitabine or tenofovir disoproxil fumarate/emtricitabine and raltegravir [c] (TAF 25 mg/FTC or TDF 300 mg/FTC and RAL HD; Descovy or Truvada and Isentress HD)	<ul style="list-style-type: none"> For TAF/FTC, initiate only in patients with CrCl ≥30 mL/min [d]. Contains 25 mg of TAF, unboosted [c]. For TDF/FTC, initiate only in patients with CrCl ≥50 mL/min [d]. For TDF/FTC, consider bone mineral density. Administer as TAF/FTC or TDF/FTC once daily and RAL HD 1,200 mg once daily, dosed as two 600 mg HD tablets. To date, no clinical trials have been conducted with TAF and RAL; data are based on bioequivalence pharmacokinetic studies. Mg- or Al-containing antacids are contraindicated; coadministration of Ca-containing antacids is not recommended with RAL HD. 	A2
<p>Abbreviations: Al, aluminum; ART, antiretroviral therapy; Ca, calcium; CrCl, creatinine clearance; Mg, magnesium.</p> <p>Notes:</p> <p>a. For recommended ART regimens in pregnant patients with HIV-2, see Table 3: ART Regimens for Initial Treatment of Pregnant Adults With HIV-2.</p> <p>b. See Use of Dolutegravir in Individuals of Childbearing Capacity.</p> <p>c. Substitutions: – In all cases, FTC and 3TC are interchangeable. – TAF 10 mg and TAF 25 mg are not interchangeable.</p> <p>d. For dose adjustments, refer to the NYSDOH AI guideline Selecting an Initial ART Regimen > Table 9: Recommended Dose Adjustments for Use of Selected Fixed-Dose Combination Antiretroviral Medications in Patients With Hepatic or Renal Impairment.</p>		

Table 2: Alternative ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2 [a]

(listed alphabetically; for specific details, see drug package inserts; for full recommendations on initiating ART in patients with HIV-1, see the NYSDOH AI guideline [Selecting an Initial ART Regimen](#))

Regimen	Comments	Rating
<i>Available as a Single-Tablet Formulation</i>		
Tenofovir alafenamide/emtricitabine/darunavir/cobicistat [b] (TAF 10 mg/FTC/DRV/COBI; Symtuza)	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min [c]. Carefully consider drug-drug interactions with COBI [Eron, et al. 2018]. Contains 10 mg TAF, boosted with COBI [b]. 	B2
Tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat [b] (TAF 10 mg/FTC/EVG/COBI; Genvoya)	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min [c]. Carefully consider drug-drug interactions with COBI. Contains 10 mg of TAF, boosted with COBI [b]. Separate dosing of Al-, Ca-, and Mg-containing antacids by 2 hours, either before or after EVG. 	B1
<i>Available as a Multi-Tablet Regimen With Twice-Daily Dosing</i>		
Tenofovir alafenamide/emtricitabine or tenofovir disoproxil fumarate/emtricitabine and raltegravir [b] (TAF 25 mg/FTC or TDF 300 mg/FTC and RAL; Descovy or Truvada and Isentress)	<ul style="list-style-type: none"> For TAF/FTC, initiate only in patients with CrCl \geq30 mL/min [c]. For TDF/FTC, initiate only in patients with CrCl \geq50 mL/min [c]. For TDF/FTC, consider bone mineral density. Administer as TAF/FTC or TDF/FTC once daily and RAL 400 mg twice daily. Al- or Mg-containing antacids are contraindicated; Ca-containing antacids are acceptable with RAL. 	B3
<p>Abbreviations: Al, aluminum; ART, antiretroviral therapy; Ca, calcium; CrCl, creatinine clearance; Mg, magnesium.</p> <p>Notes:</p> <p>a. For recommended ART regimens in pregnant patients with HIV-2, see Table 3: ART Regimens for Initial Treatment of Pregnant Adults With HIV-2.</p> <p>b. Substitutions:</p> <ul style="list-style-type: none"> In all cases, FTC and 3TC are interchangeable. TAF 10 mg and TAF 25 mg are not interchangeable. COBI and ritonavir should not be considered interchangeable because of their drug-interaction profiles. <p>c. For dose adjustments, refer to the NYSDOH AI guideline Selecting an Initial ART Regimen > Table 9: Recommended Dose Adjustments for Use of Selected Fixed-Dose Combination Antiretroviral Medications in Patients With Hepatic or Renal Impairment.</p>		

Reference

Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. *AIDS* 2018;32(11):1431-42. [PMID: 29683855]
<https://pubmed.ncbi.nlm.nih.gov/29683855>